Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen
European Journal of Neurology2021Vol. 28(8), pp. 2582–2595
Citations Over TimeTop 10% of 2021 papers
Thomas Meyer, André Maier, Željko Uzelac, Tim Hagenacker, René Günther, Olivia Schreiber‐Katz, Markus Weiler, Robert Steinbach, Ute Weyen, Jan Christoph Koch, Dagmar Kettemann, Jenny Nordén, Johannes Dorst, Claudia D. Wurster, Albert C. Ludolph, Benjamin Stolte, Maren Freigang, Alma Osmanovic, Susanne Petri, Julian Großkreutz, Annekathrin Rödiger, Ramona Griep, Marcel Gaudlitz, Bertram Walter, Christoph Münch, Susanne Spittel
Abstract
Nusinersen was administered across a broad range of ages, disease durations and motor function deficits. Treatment expectations were highly differentiated and related to SMA type and functional status. Patient-reported outcomes demonstrated a positive perception of nusinersen therapy in adult patients with 5q-SMA.
Related Papers
- → P.362RAINBOWFISH: A study of risdiplam (RG7916) in newborns with pre-symptomatic spinal muscular atrophy (SMA)(2019)8 cited
- → Recent research on the treatment of spinal muscular atrophy.(2022)2 cited
- → Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): results of the phase 3 CHERISH study(2017)1 cited
- → Perspectives on models of spinal muscular atrophy for drug discovery(2004)17 cited
- → Therapeutic decisions under uncertainty in spinal muscular atrophy (decisions-SMA study): A research protocol(2021)